Background
It was observed in 1967 that, experimental serum injection of a surgeon named "GB" with acute hepatitis led to a similar disease in tamarins [
1,
2]. In 1995, two novel viruses of the Flaviviridae, called GB virus type A and B, were detected in tamarins, which could form hepatitis at the eleventh GB passage following inoculation. These viruses were not able to infect humans [
3] nonetheless, a similar human virus (named hepatitis G virus (HGV) or GBV-C) was subsequently identified [
4,
5]. In 2010, a less closely related virus (known as GBV-D) was found in bats [
6]. Only GBV-B, a 2nd species of the Hepacivirus genus, has been demonstrated to induce liver damage and hepatitis. Infection with this virus can directly lead to acute hepatitis in laboratory animal models such as tamarins [
7,
8]. In contrast, GBV-A, HGV/GBV-C not related to hepatitis. In 2011 and regarding genome structure, phylogenetic relationships, and pathogenic features of GBV viruses, it was suggested to categorize GBV-A-like viruses, HGV/GBV-C, and GBV-D as a 4th genus in the Flaviviridae, called Pegivirus (persistent GB virus) [
9]. In 2016, following taxonomy updates of the genera Hepacivirus and Pegivirus, a new human pegivirus named HHpgV-1/HPgV-2 was among them. Analysis has revealed more than 94% identity between HHpgV-1 and HPgV-2, suggesting that they are probably the same virus [
10‐
12].
HPgV-1 (formerly GBV-C/HGV) is an enveloped, + ssRNA virus of the Flaviviridae [
13], which its genome includes a single open reading frame (ORF) coding structural and non-structural proteins [
14,
15]. HPgV-1 shares a sequence homology and genomic structure, with approximately 30% resemblance, to HCV, but its genome is deficient in the E2 hypervariable area and the core sequence [
16].
In the same way as other lymphotropic viruses, HPgV-1 is distributed through parenteral and non-parenteral ways and thereby is highly prevalent in communities suffering from a high incidence of certain bloodborne infections and sexually transmitted diseases [
13].
HPgV-1 cannot induce any human diseases [
17]. So far, there has been no conclusive evidence on the possible relationship between acute or chronic hepatitis and this virus [
13,
16,
18]. However, it has positive effects on preventing the replication of HIV-1 and on extending the survivability of Ebola and HIV-1 infected patients [
19‐
21].
Today, HPgV-1 is categorized into seven genotypes and several subtypes according to the genome heterogeneity of their either completely or partially nucleotide sequences. Geographically, such genotypes and subtypes have shown different patterns of dissemination [
22].
While HPgV-1 viremia may remain for years, it is ultimately cleared and antibodies against HPgV-1 envelope glycoprotein E2 generally emerge in 50–75% of cases [
23].
The existence of HPgV-1 RNA in serum is correlated to active infection, while anti-E2 antibody detection suggests previous infection [
24]. Thus, the Anti-E2 antibody is regarded as a valuable indicator for the diagnosis of recovery from HPgV-1 infection, which can be identified after virus clearance [
25]. Detection of HPgV-1 is usually done by ELISA and RT-PCR, the two clinical tests detect E2-protein antibodies and HPgV-1 RNA, respectively [
26,
27].
In this review, we discuss the history and classification, epidemiology, transmission, life cycle, genome organization, genotypes, immunity, and detection of HPgV-1, as well as its beneficiary impacts, especially in associations and interaction with some other infections.
Conclusion
Like all viruses, HPgV-1 relies on the host for replication. Until now, not only there has been found no compelling connection between HPgV-1 and any human illness but also it tends to be defensive against HIV infection and other illnesses, emphasizing a mutually advantageous symbiotic relationship. Epidemiologic studies have identified a relationship between HPgV-1 co-infection and lower fatality rates among HIV- diseased individuals. More analysis of the interactions between HPgV-1 and HIV has the potential to open up new treatment options for HIV disease later.
On the other hand, the anti-inflammatory properties of HPgV-1 tend to be favorable in managing some immune-mediated diseases. As an example, the impact of HPgV-1 on the host immune system function may lead to the reduction in the processes for immune surveillance observed in non-Hodgkin lymphoma [
27]. An important part that still needs to be clarified is the mechanisms through which HPgV-1 infects various types of blood cells and survives in humans. Further studies should be carried out to better understanding the processes of HPgV-1 persistence and clearance in humans. Given that human pegiviruses are phylogenetically a close relative of HCV, HPgV-1 may be used as a replacement model for HCV infection to clarify pathogenesis, immunology, and HCV persistence in humans, as well as to enhance the possible production of new vaccines and immunotherapies [
133].
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.